November 9, 2022 — CinCor Pharma, Inc. announced the presentation today of Phase 2 data from its BrigHtn trial as part of the late-breaking science session at the 2022 American Heart Association (AHA) Scientific Sessions. Baxdrostat is a highly selective, once daily oral small molecule inhibitor of aldosterone synthase.


The world market for interventional X-ray and mobile C-arm equipment is forecast to reach over $4.9 billion by 2026, according to a new report from Signify Research. The world markets for Interventional X-ray systems and mobile C-arms increased by 10.2% and 15.5% respectively in 2021.



November 9, 2022 — Seven awardees were honored during the American Heart Association Scientific Sessions (AHA 2022). The AHA designates the Distinguished Scientist award for members who have “significantly advanced the understanding of cardiovascular, stroke or brain health.” A summary of the profiles offered by the AHA of its honorees follows.



Interventional cardiologists know well the phrase “change is the only constant.” This is especially relevant as innovative software solutions continue to emerge which provide value on two impactful fronts — clinical workflow and patient outcomes.



Numerous indicators make clear that the next five years will usher in extreme transformation for a multitude of industries and sectors as well as the global economy at large. This begs the question: what is driving such significant and rapid change? This big question just might be answered in two words: alternative data. 


Reflecting back, 2022 has been a productive year. It brought with it many changes and challenges, but also brought back some of the normalcy the industry has not experienced over the past two years since the onslaught of the pandemic.

November 8, 2022 — Genomic-based therapies for cardiovascular disease are emerging fast in research, and could soon be used regularly in hospitals and practices around the world — changing future treatment, said Ann Marie Schmidt, MD, FAHA.

November 8, 2022 — After hospital discharge for heart failure, people treated with either loop diuretic medication furosemide or torsemide had similar death and hospitalization rates, according to late-breaking science researchpresented today at the

Subscribe Now